Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
| CAPS Rating |
|
|---|
ANTH
VS S&P 500 (SPY)
ANTH News and Commentary
- Is Human Genome Sciences the Perfect Stock? – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- Biotechs Have No Business in This Indication – The Motley Fool
- Anthera Implodes: Is Now the Time to Buy? – The Motley Fool
- 24/7 Wall St. Closing Bell (TWX, DIS, PEP, KBH, FSLR, PLOW, FCEL, NNBR, VELT, HTH, ODC, MIDD, TODU, – 247wallst
- Does Anthera Survive? (ANTH) – 247wallst
- Mid-day Movers (TUDO, PCBC, TZYM, ANTH, CDTI) – 247wallst
- Pre-Market Most Active for Mar 12, 2012 : BAC, ING, ZOLL, YOKU, RIO, SIRI, QQQ, UN, OREX, ANTH, ABB – NASDAQ
- Zacks #5 Rank Additions for Thursday - Tale of the Tape – NASDAQ
How do you think ANTH will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
46
Outperform
5
Underperform
All-Star Players
9
Outperform
2
Underperform
Wall Street
3
Outperform
0
Underperform
RSS Headlines
Fool UK
